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OBJECTIVES: To model the long-term metabolic costs and con-
sequences of antipsychotic therapy for chronic schizophrenia.
METHODS: We developed a Markov model to simulate long-
term treatment courses of 10,000 chronic schizophrenia patients
using annual cycles over a 10-year period. The model was devel-
oped with psychiatrists, an endocrinologist, and a cardiologist
and simulated individual patients. Patient health status (comor-
bidities, lipid levels, body mass index, and blood pressure) could
change as a function of treatment-related events. Probabilities
were determined from published pooled analyses of clinical trial
data. Costs and resource utilization patterns were obtained from
published data and standard costing sources. The model esti-
mated costs of long-term consequences of weight gain, such as
diabetes and coronary heart disease. We used data from the
Framingham Heart Study and Nurses’ Health study to assess
risks for weight gain–induced diabetes and cardiovascular
events. Outcomes included total number of patients with meta-
bolic events and associated costs. RESULTS: Fewer patients
treated with ziprasidone developed diabetes compared with
other atypical antipsychotics. The greatest difference was
observed between ziprasidone and olanzapine: costs for the
entire cohort were $12.3 million vs $32.9 million for ziprasidone
vs olanzapine, respectively. Increased diabetes risk and lipid
levels translated into higher risk for CHD. At 10 years, an addi-
tional 235 olanzapine-treated patients developed CHD vs
ziprasidone. Costs were again lowest for ziprasidone compared
with other atypical antipsychotics. CONCLUSIONS: Adverse
events common to some atypical antipsychotics (ie, weight gain)
can have a deleterious long-term metabolic impact and should
be considered when prescribing an agent for the treatment of
schizophrenia.
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OBJECTIVES: To perform an economic evaluation of Puregon
Pen and the conventional syringe system with menotropin in the
treatment of IVF/ICSI by comparing the process-utilities and the
costs for the current Dutch situation. METHODS: A conjoint
analysis (CA) was performed to express the preference of women
for the different administration forms of FSH as process-utilities
ranging from 0 to 1. In the CA, women were asked to give their
preference for the different administration forms that were
described by the levels of ﬁve attributes. A decision analytic
model was developed to estimate the costs of an average IVF
cycle in The Netherlands from the societal perspective. Epi-
demiologic and costing data were drawn from the available 
literature or were provided by experts. RESULTS: The process-
utility was estimated to be 2.6 (p < 0.05) higher for Puregon Pen
compared to the conventional syringe containing menotropin.
On a scale from 0 to 1, the process-utility was 0.96 (CI between
0.94 and 0.97) for Puregon Pen and 0.36 (CI: 0.30–0.46) for the
conventional syringe, resulting in an incremental process-utility
between 0.57 and 0.61. The additional costs per cycle for this
increase are estimated to be €60–194. CONCLUSIONS: Com-
pared with the conventional menotropin administration form,
the added value of Puregon Pen was 2.6 times higher at an extra
cost per cycle of €60–194. The comparison shows that the utility-
gain is substantial and that the additional costs are minimal.
Therefore, it can be concluded that Puregon Pen is a cost-effec-
tive administration form.
PMW2
HOW MUCH DOES UNINTENDED PREGNANCY COST THE
UK HEALTH CARE SYSTEM?
Sonnenberg F1, Price M2, Neslusan C3
1UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ,
USA; 2Janssen-Cilag, High Wycombe, Buckinghamshire, UK; 3Johnson &
Johnson Pharmaceutical Services, New Brunswick, NJ, USA
OBJECTIVES: Unplanned pregnancy can have a signiﬁcant
impact on the individuals involved. With around one-third of
pregnancies being unplanned, it is a signiﬁcant problem for
health care systems and society. The objective of this analysis was
to estimate the cost of unintended pregnancy from a UK
National Health Service perspective using a decision-analytic
modelling approach. METHODS: The cost of unintended preg-
nancy was evaluated using a decision-analytic Markov model. A
review of medical literature and government statistics was under-
taken to identify probabilities of alternative pregnancy out-
comes. The model was then used to predict the likelihood of
these outcomes: ectopic pregnancy; spontaneous abortion;
induced abortion; vaginal delivery; C-section; full term/pre-term
delivery. Costs were derived from NHS reference costs and the
literature and inﬂated to 2002 prices. Post-natal costs were
excluded. To obtain a stable estimate of costs, we simulated a
cohort of 100,000 women using oral contraceptives (OC’s) over
a 2-year period. RESULTS: The model predicts that in this
cohort of 100,000 OC users there would be 14,211 pregnancies
over two years (approximately 7% per annum). The most
common outcomes were vaginal delivery (53%), elective abor-
tion (26%) and C-section (12%). The annual cost of these events
was 10.3 million pounds (GBP), with an average event cost of
1460GBP, varying from 2448GBP for C-sections to 452GBP for
spontaneous abortions. Assuming that 30% of the 764,000 con-
ceptions that occurred in 2001 were unplanned, this would
equate to a total annual cost of 335 million GBP in the UK.
CONCLUSIONS: Unintended pregnancy places a large ﬁnancial
burden on the NHS. Investment in interventions that reduce
unintended pregnancy rates are needed.
PMW3
IMPROVING THE DELIVERY OF CHILD AND MATERNAL
HEALTH CARE IN A POOR SETTING: COSTS AND BARRIERS
TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO
MOTHER-BABY PACKAGE IN MORELOS, MEXICO
Cahuana L1, Sosa S2, Bertozzi S1
1National Institute of Public Health, Cuernavaca, Morelos, Mexico;
2University of York, Heslington,York, UK
OBJECTIVES: Analyze the incremental cost that would be
incurred if the WHO Mother-Baby Package standards were
